Acute myeloid leukemia

What Is Acute Myeloid Leukemia?

Acute myeloid leukemia is a blood cancer defined by the presence of abnormal, immature cells called myeloblasts making up at least twenty percent of the cells found in the blood or bone marrow, replacing the healthy cells needed for normal function.¹

The disease actually represents a heterogeneous group of related disorders rather than a single uniform condition, historically classified according to which normal bone marrow cell type the abnormal blasts most closely resemble, and more recently reclassified by the World Health Organization to incorporate specific genetic and molecular features alongside these traditional classifications.¹

This shift toward genetic classification reflects a broader transformation in how acute myeloid leukemia is understood, since specific mutations, rather than appearance alone, increasingly guide both prognosis and treatment selection for individual patients.¹

Acute myeloid leukemia comprises a heterogeneous group of neoplastic disorders in which at least twenty percent of cells in the blood or bone marrow are myeloblasts.
National Center for Biotechnology Information

Symptoms

Weakness, easy fatigue, and pallor are found consistently across essentially all forms of acute myeloid leukemia, reflecting the anemia that develops as leukemic cells crowd out healthy red blood cell production.¹

Fever represents another common symptom, appearing in the large majority of patients across most disease subtypes, generally reflecting the body’s impaired ability to fight infection due to insufficient functional white blood cells.¹

Bleeding symptoms vary somewhat depending on the specific disease subtype, appearing with particular frequency in one subtype associated with a distinctive and dangerous bleeding tendency, underscoring why identifying the exact leukemia subtype matters clinically.¹

Causes

Acute myeloid leukemia arises when myeloid precursor cells within the bone marrow acquire genetic mutations that block their normal maturation process while simultaneously driving uncontrolled proliferation.¹

Certain specific mutations occur with notable frequency in the disease, including alterations affecting a gene called NPM1, present in roughly thirty percent of patients, and mutations affecting the FLT3 gene, both of which carry meaningful implications for prognosis and treatment selection.²

Because these genetic changes vary so widely between patients, acute myeloid leukemia is increasingly understood not as a single disease but as a spectrum of related conditions, each shaped by its own particular combination of underlying mutations.¹

Risk Factors

Age at diagnosis varies meaningfully across the different disease subtypes, with some forms typically diagnosed in younger adults around their late twenties, while other subtypes occur more commonly in middle age, illustrating how the disease’s risk profile shifts depending on its specific molecular characteristics.¹

Older adults represent a particularly important population within acute myeloid leukemia, since this group often presents with additional health complexities that must be carefully weighed when selecting appropriate treatment intensity.³

Specific genetic mutations, including those affecting FLT3 and NPM1, represent identifiable risk related features found in a meaningful proportion of patients, helping clinicians stratify individual risk and anticipate likely disease behavior.²

Complications

Bleeding complications represent a significant concern in acute myeloid leukemia, with certain disease subtypes carrying a particularly elevated risk of serious bleeding requiring urgent recognition and management.¹

Older patients with acute myeloid leukemia often face a more complex clinical picture, since age related health conditions can meaningfully limit which treatments are safely tolerated, making individualized assessment essential rather than relying on a single standard approach.³

Determining a patient’s overall fitness for treatment, often through structured comorbidity scoring and geriatric assessment tools, has become an increasingly important part of managing complications and selecting appropriately tailored therapy.³

Treatment

Targeted therapy has meaningfully changed the treatment landscape for patients with specific genetic mutations, with FLT3 inhibitors such as midostaurin now approved for use alongside standard chemotherapy in newly diagnosed patients carrying this particular mutation.²

For older or less fit patients who may not tolerate intensive chemotherapy, combination regimens pairing venetoclax with hypomethylating agents have produced notably high remission rates, particularly among patients with NPM1 mutations, where combination treatment achieved remission in the large majority of patients compared to considerably lower rates with less intensive approaches.⁴

Emerging triplet regimens, combining a hypomethylating agent, venetoclax, and a FLT3 inhibitor, have shown even higher remission rates than two drug combinations among older or less fit patients with FLT3 mutated disease, reflecting ongoing efforts to tailor treatment intensity to each patient’s individual disease biology and overall fitness.⁴

Prevention

Because acute myeloid leukemia typically arises from mutations acquired over a person’s lifetime rather than a single identifiable external cause, there is no reliable way to prevent the disease in most patients.

For older adults specifically, individualized assessment of overall fitness and disease biology, rather than treatment based on age alone, plays an important role in optimizing outcomes and minimizing unnecessary treatment related complications.³

Genetic testing at diagnosis allows treatment to be tailored to a patient’s specific mutation profile from the outset, supporting a more precise, individualized approach to both prognosis and therapy selection.²

Why Visual Communication Matters for Acute Myeloid Leukemia

Explaining how the same broad diagnosis can actually represent dozens of biologically distinct diseases, each shaped by different genetic mutations, requires visuals that clearly convey this complexity without overwhelming patients facing a difficult diagnosis.

Pharmaceutical companies, hematology and oncology practices, and patient education organizations rely on clear illustration and animation to explain acute myeloid leukemia and support informed, individualized treatment decisions.

• Illustrating how genetic mutations disrupt normal myeloid cell maturation
• Animating the distinction between different leukemia subtypes and their behavior
• Explaining the mechanism of action of FLT3 inhibitors and venetoclax
• Visualizing how treatment intensity is tailored to age and overall fitness
• Supporting patient education on genetic testing and personalized treatment
• Creating training materials for hematology and oncology clinicians

How Biotic Artlab Supports Acute Myeloid Leukemia Communication

We work with pharmaceutical companies, hematology and oncology practices, and patient advocacy organizations to create scientifically accurate visuals that make acute myeloid leukemia and its treatment easier to understand.

• Custom 3D animations of myeloid cell maturation and genetic mutation effects
• Detailed illustrations comparing leukemia subtypes and molecular classification
• Mechanism of action animations for targeted therapies and combination regimens
• Patient facing materials on genetic testing and individualized treatment planning
• Clinical training content for hematology, oncology, and geriatric care teams
• Conference presentations and marketing visuals for blood cancer audiences

Frequently Asked Questions

Is acute myeloid leukemia a single disease?

Not exactly. It represents a heterogeneous group of related disorders, increasingly classified by specific genetic and molecular features rather than appearance alone.¹

What are common early symptoms of acute myeloid leukemia?

Weakness, fatigue, pallor, and fever are found consistently across nearly all disease subtypes, reflecting reduced healthy blood cell production.¹

What are FLT3 and NPM1 mutations?

These are among the most common genetic mutations found in acute myeloid leukemia, each carrying specific implications for prognosis and treatment selection.²

How is acute myeloid leukemia treated in older patients?

Older or less fit patients often receive venetoclax combined with hypomethylating agents rather than intensive chemotherapy, achieving high remission rates in appropriately selected patients.⁴

What is a FLT3 inhibitor?

FLT3 inhibitors such as midostaurin are targeted medications used alongside chemotherapy for patients whose leukemia carries a FLT3 mutation.²

Why does age matter so much in treatment decisions?

Older patients often have additional health conditions that affect which treatments are safely tolerated, making individualized fitness assessment essential to treatment planning.³

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to acute myeloid leukemia or hematologic oncology, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Classification of Acute Myeloid Leukemia.
2. National Center for Biotechnology Information. Targeting FLT3 Mutation in Acute Myeloid Leukemia, Current Strategies and Future Directions.
3. National Center for Biotechnology Information. Older Patients With Acute Myeloid Leukemia Deserve Individualized Treatment.
4. National Center for Biotechnology Information. Hypomethylating Agent and Venetoclax With FLT3 Inhibitor Triplet Therapy in Older Unfit Patients With FLT3 Mutated AML.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.